Trial Profile

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications Acquired immunodeficiency syndrome
Focus Pharmacokinetics
Sponsors Elea

Most Recent Events

11 Apr 2016 New trial record
06 Apr 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
06 Apr 2016 Primary endpoint (Area Under the Curve [AUC]) has been met, as per the results published in the International Journal of Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com